The influence of hydroxypropyl-β-cyclodextrin on the solubility, dissolution, cytotoxicity, and binding of riluzole with human serum albumin

Journal of Pharmaceutical and Biomedical Analysis

Volumn 117, Issue , 2016, Pages 453-463

  Wang, Lili ^a   Yan, Jin ^a   Li, Yaping ^a   Xu, Kailin ^a   Li, Shanshan ^a   Tang, Peixiao ^a   Li, Hui ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Human serum albumin; Hydroxypropyl cyclodextrin; Inclusion complex; Influence; Riluzole; Solubilization

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; HUMAN SERUM ALBUMIN; RILUZOLE; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; CYTOTOXIN; PROTEIN BINDING; SERUM ALBUMIN;

ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG BINDING; DRUG SOLUBILITY; FLUORESCENCE SPECTROSCOPY; INFRARED SPECTROSCOPY; MOLECULAR MODEL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POWDER X RAY DIFFRACTION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCANNING ELECTRON MICROSCOPY; THERMODYNAMICS; THERMOGRAVIMETRY; X RAY DIFFRACTION; CHEMISTRY; HUMAN; METABOLISM; PHYSIOLOGY; SOLUBILITY;

BETA-CYCLODEXTRINS; CYTOTOXINS; HUMANS; MODELS, MOLECULAR; PROTEIN BINDING; RILUZOLE; SERUM ALBUMIN; SOLUBILITY;

EID: 84943595814     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2015.09.033     Document Type: Article

References (52)

1. Szejtli J. Introduction and general overview of cyclodextrin chemistry. Chem. Rev. 1998, 98:1743-1754.
2. Loftsson T., Brewster M.E. Pharmaceutical applications of cyclodextrins: basic science and product development. J. Pharm. Pharmacol. 2010, 62:1607-1621.
3. Uekama K., Hirayama F., Irie T. Cyclodextrin drug carrier systems. Chem. Rev. 1998, 98:2045-2076.
4. Mangolim C.S., Moriwaki C., Nogueira A.C., Sato F., Baesso M.L., Neto A.M., Matioli G. Curcumin-β-cyclodextrin inclusion complex: stability, solubility, characterisation by FT-IR, FT-Raman, X-ray diffraction and photoacoustic spectroscopy, and food application. Food Chem. 2014, 153:361-370.
5. Breslow R., Dong S.D. Biomimetic reactions catalyzed by cyclodextrins and their derivatives. Chem. Rev. 1998, 98:1997-2012.
6. Schurig V., Nowotny H.P. Gas chromatographic separation of enantiomers on cyclodextrin derivatives. Angew. Chem. Int. Ed. 1990, 29:939-957.
7. Yang R., Li K.A., Wang K., Zhao F., Li N., Liu F. Porphyrin assembly on β-cyclodextrin for selective sensing and detection of a zinc ion based on the dual emission fluorescence ratio. Anal. Chem. 2003, 75:612-621.
8. Loftsson T., Duchene D. Cyclodextrins and their pharmaceutical applications. Int. J. Pharm. 2007, 329:1-11.
9. Aiassa V., Zoppi A., Albesa I., Longhi M.R. Inclusion complexes of chloramphenicol with β-cyclodextrin and aminoacids as a way to increase drug solubility and modulate ROS production. Carbohydr. Polym. 2015, 121:320-327.
10. Mennini N., Bragagni M., Maestrelli F., Mura P. Physico-chemical characterization in solution and in the solid state of clonazepam complexes with native and chemically-modified cyclodextrins. J. Pharm. Biomed. Anal. 2014, 89:142-149.
11. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 1999, 58:29-36.
12. Omidvar Z., Parivar K., Sanee H., Amiri-Tehranizadeh Z., Baratian A., Saberi M.R., Asoodeh A., Chamani J. Investigations with spectroscopy, zeta potential and molecular modeling of the non-cooperative behaviour between cyclophosphamide hydrochloride and aspirin upon interaction with human serum albumin: binary and ternary systems from the view point of multi-drug therapy. J. Biomol. Struct. Dyn. 2011, 29:181-206.
13. Chi Z., Liu R. Phenotypic characterization of the binding of tetracycline to human serum albumin. Biomacromolecules 2010, 12:203-209.
14. Yang Q., Zhou X.-M., Chen X.-G. Combined molecular docking and multi-spectroscopic investigation on the interaction between eosin B and human serum albumin. J. Lumin. 2011, 131:581-586.
15. Hu T., Liu Y. Probing the interaction of cefodizime with human serum albumin using multi-spectroscopic and molecular docking techniques. J. Pharm. Biomed. Anal. 2015, 107:325-332.
16. Iranfar H., Rajabi O., Salari R., Chamani J. Probing the interaction of human serum albumin with ciprofloxacin in the presence of silver nanoparticles of three sizes: multispectroscopic and ζ potential investigation. J. Phys. Chem. B 2012, 116:1951-1964.
17. Yan J., Wu D., Ma X., Wang L., Xu K., Li H. Spectral and molecular modeling studies on the influence of β-cyclodextrin and its derivatives on aripiprazole-human serum albumin binding. Carbohydr. Polym. 2015, 131:65-74.
18. Doble A. The pharmacology and mechanism of action of riluzole. Neurology 1996, 47:233S-241S.
19. Pratt J., Rataud J., Bardot F., Roux M., Blanchard J.-C., Laduron P.M., Stutzmann J.-M. Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischaemia. Neurosci. Lett. 1992, 140:225-230.
20. Bruno R., Vivier N., Montay G., Le Liboux A., Powe L.K., Delumeau J.-C., Rhodes G.R. Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis. Clin. Pharmacol. Ther. 1997, 62:518-526.
21. Cheah B., Vucic S., Krishnan A., Kiernan M. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr. Med. Chem. 2010, 17:1942-1959.
22. Wang L., Li S., Tang P., Yan J., Xu K., Li H. Characterization and evaluation of synthetic riluzole with beta-cyclodextrin and 2,6-di-O-methyl-beta-cyclodextrin inclusion complexes. Carbohydr. Polym. 2015, 129:9-16.
23. Davis M.E., Brewster M.E. Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev. Drug Discov. 2004, 3:1023-1035.
24. Irie T., Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. 1997, 86:147-162.
25. Duchene D., Wouessidjewe D. Physicochemical characteristics and pharmaceutical uses of cyclodextrin derivatives, Part II. Pharm. Tech. 1990, 14:26-34.
26. Liu J., Qiu L., Gao J., Jin Y. Preparation, characterization and in vivo evaluation of formulation of baicalein with hydroxypropyl-β-cyclodextrin. Int. J. Pharm. 2006, 312:137-143.
27. Painter L., Harding M.M., Beeby P.J. Synthesis and interaction with human serum albumin of the first 3,18-disubstituted derivative of bilirubin. J. Chem. Soc. Perk. Trans. 1 1998, 18:3041-3044.
28. Higuchi T., Connors K.A. Phase-solubility techniques. Adv. Anal. Chem. Instrum. 1965, 4:117-212.
29. Rakotoarivelo N.V., Perio P., Najahi E., Nepveu F. Interaction between antimalarial 2-aryl-3H-indol-3-one derivatives and human serum albumin. J. Phys. Chem. B 2014, 118:13477-13485.
30. Vandelli M., Ruozi B., Forni F., Mucci A., Salvioli G., Galli E. A solution and solid state study on 2-hydroxypropyl-β-cyclodextrin complexation with hyodeoxycholic acid. J. Incl. Phenom. Macro. 2000, 37:237-251.
31. Üner M. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Die Pharmazie-An Int. J. Pharm. Sci. 2006, 61:375-386.
32. Su Y., Rao S., Cai Y., Yang Y. Preparation and characterization of the inclusion complex of hypocrellin A with hydroxypropyl-β-cyclodextrin. Eur. Food Res. Technol. 2010, 231:781-788.
33. Huang Z., Tian S., Ge X., Zhang J., Li S., Li M., Cheng J., Zheng H. Complexation of chlorpropham with hydroxypropyl-β-cyclodextrin and its application in potato sprout inhibition. Carbohydr. Polym. 2014, 107:241-246.
34. Sancho M.I., Russo M.G., Sergio Moreno M., Gasull E., Blanco S.E., Narda G.E. Physicochemical characterization of 2-hydroxybenzophenone with beta-cyclodextrin in solution and solid state. J. Phys. Chem. B 2015, 119:5918-5925.
35. Mura P. Analytical techniques for characterization of cyclodextrin complexes in the solid state: a review. J. Pharm. Biomed. Anal. 2015, 113:226-238.
36. 1H NMR and molecular modeling studies. Carbohydr. Polym. 2012, 89:492-496.
37. 1HNMR, EPR, and optical studies. Free Radical Bio. Med. 2004, 36:872-880.
38. Schneider H.-J., Hacket F., Rüdiger V., Ikeda H. NMR studies of cyclodextrins and cyclodextrin complexes. Chem. Rev. 1998, 98:1755-1786.
39. Charoenchaitrakool M., Dehghani F., Foster N. Utilization of supercritical carbon dioxide for complex formation of ibuprofen and methyl-β-cyclodextrin. Int. J. Pharm. 2002, 239:103-112.
40. Banchero M., Ronchetti S., Manna L. Characterization of ketoprofen/methyl-β-cyclodextrin complexes prepared using supercritical carbon dioxide. J. Chem. 2013, 2013:1-8.
41. Grant P., Lougee L., Hirschtritt M., Swedo S.E. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J. Child Adolesc. Psychopharmacol. 2007, 17:761-767.
42. Kiss T., Fenyvesi F., Bácskay I., Váradi J., Fenyvesi E., Iványi R., Szente L., Tosaki A., Vecsernyés M. Evaluation of the cytotoxicity of β-cyclodextrin derivatives: evidence for the role of cholesterol extraction. Eur. J. Pharm. Sci. 2010, 40:376-380.
43. Zhang L., Zhang Z., Li N., Wang N., Wang Y., Tang S., Xu L., Ren Y. Synthesis and evaluation of a novel β-cyclodextrin derivative for oral insulin delivery and absorption. Int. J. Biol. Macromol. 2013, 61:494-500.
44. Sudha N., Sameena Y., Chandrasekaran S., Enoch I.V.M.V., Premnath D. Alteration of the binding strength of dronedarone with bovine serum albumin by β-cyclodextrin: a spectroscopic study. Spectrosc. Lett. 2014, 48:112-119.
45. Ware W.R. Oxygen quenching of fluorescence in solution: an experimental study of the diffusion process. J. Phys. Chem. 1962, 66:455-458.
46. Ghosh S., Paul B.K., Chattopadhyay N. Interaction of cyclodextrins with human and bovine serum albumins: a combined spectroscopic and computational investigation. J. Chem. Sci. 2014, 126:931-944.
47. Wang C., Wu Q.-H., Li C.-R., Wang Z., Ma J.-J., Zang X.-H., Qin N.-X. Interaction of tetrandrine with human serum albumin: a fluorescence quenching study. Anal. Sci. 2007, 23:429-433.
48. Ehteshami M., Rasoulzadeh F., Mahboob S., Rashidi M.-R. Characterization of 6-mercaptopurine binding to bovine serum albumin and its displacement from the binding sites by quercetin and rutin. J. Lumin. 2013, 135:164-169.
49. Yan J., Wang Q., Pan Q., Rao Z., Su Y., Li H. Assessment of the interaction between fraxinellone and bovine serum albumin by optical spectroscopy and molecular modeling methods. J. Lumin. 2013, 137:180-185.
50. Sudlow G., Birkett D., Wade D. Further characterization of specific drug binding sites on human serum albumin. Mol. Pharmacol. 1976, 12:1052-1061.
51. Sudlow G., Birkett D.J., Wade D.N. Characterization of 2 specific drug binding-sites on humain-serum albumin. Mol. Pharmacol. 1975, 11:824-832.
52. Bhattacharya A.A., Curry S., Franks N.P. Binding of the general anesthetics propofol and halothane to human serum albumin high resolution crystal structures. J. Biol. Chem. 2000, 275:38731-38738.